New Vaccines in the Pipeline 2019

New Delivery Systems
Combination vaccines are advantageous because they mitigate the burden of multiple injections, reduce the number of visits, and save on costs for storage and shipment In 2018, the FDA approved a new hexavalent vaccine, DTaP5-HB-IPV- Hib (Vaxelis, Merck) for primary and booster vaccination in infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive disease caused by Haemophilus influenzae type b.

There is a trend in the industry, particularly in flu vaccines, to administer the vaccinations intradermal (into the skin), as opposed into the muscle. This lowers the chance of a shoulder injury due to vaccine administration (SIRVA).

Gold Law Firm, LLC. assists those injured from vaccines. The National Vaccine Injury Compensation Program compensates vaccine injuries. These cases are heard in the United States Court of Federal Claims, otherwise known as the vaccine court.

0 thoughts on “New Vaccines in the Pipeline 2019”

Leave a Reply

Your email address will not be published. Required fields are marked *